A method includes delivering a composition to a tissue site within a volume of tissue; and at least one of monitoring the effect of the composition on an electrophysiological state of a region in the volume of tissue and monitoring the migration of the composition in the region after delivery to the site; wherein the composition comprises an ablative agent for performing a treatment within a body of a subject and an excipient for limiting migration of at least one of the composition and the ablative agent within the body after delivery to the tissue site.

A neurostimulation system provides for capture verification and stimulation intensity adjustment to ensure effectiveness of vagus nerve stimulation in modulating one or more target functions in a patient. In various embodiments, stimulation is applied to the vagus nerve, and evoked responses are detected to verify that the stimulation captures the vagus nerve and to adjust one or more stimulation parameters that control the stimulation intensity.

A method of guiding a cardiac treatment using a functional imaging modality, comprising: providing functional imaging modality data from a functional imaging modality which images an intrabody volume of a patient containing a heart, the patient having been injected with an imaging agent having a nervous tissue uptake by an autonomic nervous system (ANS) of the heart, the ANS comprising at least one GP; locating the at least one GP innervating the heart based on the functional imaging modality data; and providing the located at least one GP.

Systems, devices, and methods are described for neuromonitoring. A minimum stimulus signal required to elicit a threshold neuromuscular response is determined by delivery of stimulus signals to tissue and detection of neuromuscular responses in muscle tissue. The strength of the delivered stimulus signals is varied, for example by adjusting the current amplitude or pulse width of the signals, and muscle responses are measure, for example by detecting EMG signals. The delivered stimuli and corresponding responses are then used to determine a stimulation threshold. The stimulation threshold may be used to indicate at least one of nerve proximity and pedicle integrity.

A neural interfacing device is disclosed. The neural interfacing device may include at least one microneedle electrode. The microneedle electrode may have one or more microneedles. The one or more microneedles may be shaped and positioned such that when the neural interfacing device is applied to a nerve, the one or more microneedles penetrate a nerve epineurium without any portion of the microneedle electrode penetrating any nerve axon beyond a depth of 500 micrometers.

Systems and methods for treating a fibrous mass, which is comprised of a Morton's neuroma, are disclosed. In one exemplary implementation, a method may comprise identifying a location of the fibrous mass and non-surgically delivering electromagnetic energy to the fibrous mass. Embodiments may include delivering the energy via a Nd:Yag laser at various specified parameters, such as spot size, power/fluence, frequency, duration, pulse characteristics, and/or tissue depth, among others.

A magnetic measuring apparatus includes an inclination gantry including a mount surface and an inclined surface that is inclined with respect to the mount surface, a cryostat disposed on the inclined surface, a cryocooling system connected to the cryostat, a sensor tube connected to the cryostat and including a curved surface that does not curve in a predetermined direction and curves in a direction orthogonal to the predetermined direction such that a center of the curved surface protrudes with respect to side edges of the curved surface, and a magnetic sensor that measures biomagnetism and is housed in the sensor tube such that a sensor surface of the magnetic sensor faces the curved surface. The sensor surface is inclined with respect to the mount surface in a direction that is the same as a direction in which the inclined surface is inclined.

Various methods and machines have been used in the past to measure electrical characteristics of living tissue for purpose of locating an area of abnormal nervous system activity. However, whereas prior art methodologies merely allow for the detection of pain, the apparatus, system and method of the present invention allow for the objective assessment of autonomic nerve function and/or pain severity. As such, the present invention finds utility not only the initial diagnosis, including the early diagnosis of generally asymptomatic autonomic dysfunction, but also the on-going treatment of any disease, disorder or injury associated therewith. To that end, the apparatus, system and method of the present invention allows medical practitioners to non-invasively and quantitatively distinguish the organic from the psychosomatic and legitimate pain patients from drug seekers and opioid addicts, as well as to directly and objectively compare the efficacy of different drug regimens and therapy protocols.

Electrical probe assemblies, such as nerve probe assemblies, are disclosed herein. In one example implementation, a nerve probe assembly may include an electrical probe including an electrode disposed on or about an end thereof for electrically stimulating tissue or recording stimulated tissue activity, an axial length of the electrical probe including a shapeable part; a rigid sheathing adapted to cover and thereby inhibit a portion of the shapeable part of the axial length of the electrical probe from being shaped, the portion of the shapeable part covered by the rigid sheathing being adjustable; and a handle and an adjustment structure affixed to respective ones of the electrical probe and the rigid sheathing, the handle and the adjustment structure adapted to cooperate to enable adjustment of the portion of the shapeable part of the axial length of the electrical probe covered by the rigid sheathing.

The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.